Compare SRTS & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRTS | GANX |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.5M | 72.7M |
| IPO Year | 2016 | 2021 |
| Metric | SRTS | GANX |
|---|---|---|
| Price | $4.45 | $1.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $6.67 | ★ $7.50 |
| AVG Volume (30 Days) | 38.2K | ★ 712.5K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,482,000.00 | $55,180.00 |
| Revenue This Year | $2.00 | N/A |
| Revenue Next Year | $34.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.03 | $1.41 |
| 52 Week High | $5.92 | $4.34 |
| Indicator | SRTS | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 58.74 | 39.30 |
| Support Level | $3.66 | $1.55 |
| Resistance Level | $4.80 | $2.03 |
| Average True Range (ATR) | 0.27 | 0.15 |
| MACD | 0.07 | -0.02 |
| Stochastic Oscillator | 87.34 | 27.03 |
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.